Potential liver toxicity prompts Lilly to stop Alzheimer's drug study

06/16/2013 | Reuters

Eli Lilly and Co. has discontinued a Phase II trial of its investigational Alzheimer's disease drug LY2886721, a beta secretase inhibitor, after cases of abnormal liver tests were identified. Lilly believes the liver problems are not linked to how the drug works, and it still wants to develop beta secretase inhibitors for Alzheimer's.

View Full Article in:


Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Attorney
Blue Cross Blue Shield of Louisiana
Baton Rouge, LA
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
Chief Financial Officer
Health Alliance Plan of Michigan
Southfield, MI
Senior Vice-President Managed Care Mid-Atlantic Region
Mercy Health System
Conshohocken, PA
Associate Chief Financial Officer
Commonwealth Care Alliance
Boston, MA